Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy
Abstract
:1. Introduction
2. Results
3. Discussion
4. Materials and Methods
4.1. Patient Selection and Data Collection
4.2. Single Nucleotide Polymorphism (SNP) Selection and Genotyping
4.3. Human Tissue cDNA Array and TaqMan® qRT-PCR Analysis
4.4. Statistical Analysis
4.5. Bioinformatics Analysis
5. Conclusions
Supplementary Materials
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Djulbegovic, M.; Beyth, R.J.; Neuberger, M.M.; Stoffs, T.L.; Vieweg, J.; Djulbegovic, B.; Dahm, P. Screening for prostate cancer: Systematic review and meta-analysis of randomised controlled trials. BMJ 2010, 341, c4543. [Google Scholar] [CrossRef] [PubMed]
- Harris, W.P.; Mostaghel, E.A.; Nelson, P.S.; Montgomery, B. Androgen deprivation therapy: Progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 2009, 6, 76–85. [Google Scholar] [CrossRef] [PubMed]
- Horwitz, E.M. Prostate cancer: Optimizing the duration of androgen deprivation therapy. Nat. Rev. Urol. 2009, 6, 527–529. [Google Scholar] [CrossRef] [PubMed]
- Walczak, J.R.; Carducci, M.A. Prostate cancer: A practical approach to current management of recurrent disease. Mayo Clin. Proc. 2007, 82, 243–249. [Google Scholar] [CrossRef]
- Pienta, K.J.; Bradley, D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res. 2006, 12, 1665–1671. [Google Scholar] [CrossRef] [PubMed]
- Moon, R.T.; Miller, J.R. The APC tumor suppressor protein in development and cancer. Trends Genet. 1997, 13, 256–258. [Google Scholar] [CrossRef]
- Spink, K.E.; Polakis, P.; Weis, W.I. Structural basis of the axin-adenomatous polyposis coli interaction. EMBO J. 2000, 19, 2270–2279. [Google Scholar] [CrossRef] [PubMed]
- Logan, C.Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781–810. [Google Scholar] [CrossRef] [PubMed]
- Katoh, M. Wnt/pcp signaling pathway and human cancer (review). Oncol. Rep. 2005, 14, 1583–1588. [Google Scholar] [CrossRef] [PubMed]
- Brennan, K.R.; Brown, A.M. Wnt proteins in mammary development and cancer. J. Mammary Gland Biol. Neoplasia 2004, 9, 119–131. [Google Scholar] [CrossRef] [PubMed]
- Brown, A.M. Wnt signaling in breast cancer: Have we come full circle? Breast Cancer Res. 2001, 3, 351–355. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Howe, L.R.; Brown, A.M. Wnt signaling and breast cancer. Cancer Biol. Ther. 2004, 3, 36–41. [Google Scholar] [CrossRef] [PubMed]
- Park, J.Y.; Park, W.S.; Nam, S.W.; Kim, S.Y.; Lee, S.H.; Yoo, N.J.; Lee, J.Y.; Park, C.K. Mutations of β-catenin and AXIN I genes are a late event in human hepatocellular carcinogenesis. Liver Int. 2005, 25, 70–76. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, M.; Wakabayashi, K. Gene mutations and altered gene expression in azoxymethane-induced colon carcinogenesis in rodents. Cancer Sci. 2004, 95, 475–480. [Google Scholar] [CrossRef] [PubMed]
- Clevers, H. Wnt breakers in colon cancer. Cancer Cell 2004, 5, 5–6. [Google Scholar] [CrossRef]
- Mulholland, D.J.; Read, J.T.; Rennie, P.S.; Cox, M.E.; Nelson, C.C. Functional localization and competition between the androgen receptor and T-cell factor for nuclear β-catenin: A means for inhibition of the Tcf signaling axis. Oncogene 2003, 22, 5602–5613. [Google Scholar] [CrossRef] [PubMed]
- Yardy, G.W.; Brewster, S.F. Wnt signalling and prostate cancer. Prostate Cancer Prostatic Dis. 2005, 8, 119–126. [Google Scholar] [CrossRef] [PubMed]
- Verras, M.; Sun, Z. Roles and regulation of wnt signaling and β-catenin in prostate cancer. Cancer Lett. 2006, 237, 22–32. [Google Scholar] [CrossRef] [PubMed]
- Bierie, B.; Nozawa, M.; Renou, J.P.; Shillingford, J.M.; Morgan, F.; Oka, T.; Taketo, M.M.; Cardiff, R.D.; Miyoshi, K.; Wagner, K.U.; et al. Activation of β-catenin in prostate epithelium induces hyperplasias and squamous transdifferentiation. Oncogene 2003, 22, 3875–3887. [Google Scholar] [CrossRef] [PubMed]
- Chesire, D.R.; Isaacs, W.B. β-catenin signaling in prostate cancer: An early perspective. Endocr. Relat. Cancer 2003, 10, 537–560. [Google Scholar] [CrossRef] [PubMed]
- Kinzler, K.W.; Nilbert, M.C.; Su, L.K.; Vogelstein, B.; Bryan, T.M.; Levy, D.B.; Smith, K.J.; Preisinger, A.C.; Hedge, P.; McKechnie, D.; et al. Identification of fap locus genes from chromosome 5q21. Science 1991, 253, 661–665. [Google Scholar] [CrossRef] [PubMed]
- Nishisho, I.; Nakamura, Y.; Miyoshi, Y.; Miki, Y.; Ando, H.; Horii, A.; Koyama, K.; Utsunomiya, J.; Baba, S.; Hedge, P.; et al. Mutations of chromosome 5q21 genes in fap and colorectal cancer patients. Science 1991, 253, 665–669. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.; Shukeir, N.; Potti, A.; Sircar, K.; Aprikian, A.; Goltzman, D.; Rabbani, S.A. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer 2004, 101, 1345–1356. [Google Scholar] [CrossRef] [PubMed]
- Verras, M.; Brown, J.; Li, X.; Nusse, R.; Sun, Z. Wnt3a growth factor induces androgen receptor-mediated transcription and enhances cell growth in human prostate cancer cells. Cancer Res. 2004, 64, 8860–8866. [Google Scholar] [CrossRef] [PubMed]
- Hieronymus, H.; Schultz, N.; Gopalan, A.; Carver, B.S.; Chang, M.T.; Xiao, Y.; Heguy, A.; Huberman, K.; Bernstein, M.; Assel, M.; et al. Copy number alteration burden predicts prostate cancer relapse. Proc. Natl. Acad. Sci. USA 2014, 111, 11139–11144. [Google Scholar] [CrossRef] [PubMed]
- Nathke, I.S. The adenomatous polyposis coli protein: The achilles heel of the gut epithelium. Annu. Rev. Cell Dev. Biol. 2004, 20, 337–366. [Google Scholar] [CrossRef] [PubMed]
- Lengauer, C.; Kinzler, K.W.; Vogelstein, B. Genetic instabilities in human cancers. Nature 1998, 396, 643–649. [Google Scholar] [CrossRef] [PubMed]
- Fodde, R.; Kuipers, J.; Rosenberg, C.; Smits, R.; Kielman, M.; Gaspar, C.; van Es, J.H.; Breukel, C.; Wiegant, J.; Giles, R.H.; et al. Mutations in the APC tumour suppressor gene cause chromosomal instability. Nat. Cell Biol. 2001, 3, 433–438. [Google Scholar] [CrossRef] [PubMed]
- Kaplan, K.B.; Burds, A.A.; Swedlow, J.R.; Bekir, S.S.; Sorger, P.K.; Nathke, I.S. A role for the adenomatous polyposis coli protein in chromosome segregation. Nat. Cell Biol. 2001, 3, 429–432. [Google Scholar] [CrossRef] [PubMed]
- Kypta, R.M.; Waxman, J. Wnt/β-catenin signalling in prostate cancer. Nat. Rev. Urol. 2012, 9, 418–428. [Google Scholar] [CrossRef] [PubMed]
- Cho, N.Y.; Kim, J.H.; Moon, K.C.; Kang, G.H. Genomic hypomethylation and cpg island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch. 2009, 454, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Costa, V.L.; Henrique, R.; Jeronimo, C. Epigenetic markers for molecular detection of prostate cancer. Dis. Markers 2007, 23, 31–41. [Google Scholar] [CrossRef] [PubMed]
- Chen, Y.; Li, J.; Yu, X.; Li, S.; Zhang, X.; Mo, Z.; Hu, Y. APC gene hypermethylation and prostate cancer: A systematic review and meta-analysis. Eur. J. Hum. Genet. 2013, 21, 929–935. [Google Scholar] [CrossRef] [PubMed]
- Huang, S.P.; Ting, W.C.; Chen, L.M.; Huang, L.C.; Liu, C.C.; Chen, C.W.; Hsieh, C.J.; Yang, W.H.; Chang, T.Y.; Lee, H.Z.; et al. Association analysis of Wnt pathway genes on prostate-specific antigen recurrence after radical prostatectomy. Ann. Surg. Oncol. 2010, 17, 312–322. [Google Scholar] [CrossRef] [PubMed]
- Bao, B.Y.; Pao, J.B.; Huang, C.N.; Pu, Y.S.; Chang, T.Y.; Lan, Y.H.; Lu, T.L.; Lee, H.Z.; Juang, S.H.; Chen, L.M.; et al. Polymorphisms inside micrornas and microrna target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin. Cancer Res. 2011, 17, 928–936. [Google Scholar] [CrossRef] [PubMed]
- Stewart, A.J.; Scher, H.I.; Chen, M.H.; McLeod, D.G.; Carroll, P.R.; Moul, J.W.; D′Amico, A.V. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure. J. Clin. Oncol. 2005, 23, 6556–6560. [Google Scholar] [CrossRef] [PubMed]
- Kwak, C.; Jeong, S.J.; Park, M.S.; Lee, E.; Lee, S.E. Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer. J. Urol. 2002, 168, 995–1000. [Google Scholar] [CrossRef]
- Choueiri, T.K.; Xie, W.; D’Amico, A.V.; Ross, R.W.; Hu, J.C.; Pomerantz, M.; Regan, M.M.; Taplin, M.E.; Kantoff, P.W.; Sartor, O.; et al. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy. Cancer 2009, 115, 981–987. [Google Scholar] [CrossRef] [PubMed]
- Ross, R.W.; Oh, W.K.; Xie, W.; Pomerantz, M.; Nakabayashi, M.; Sartor, O.; Taplin, M.E.; Regan, M.M.; Kantoff, P.W.; Freedman, M. Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer. J. Clin. Oncol. 2008, 26, 842–847. [Google Scholar] [CrossRef] [PubMed]
- De Bakker, P.I.; Yelensky, R.; Pe’er, I.; Gabriel, S.B.; Daly, M.J.; Altshuler, D. Efficiency and power in genetic association studies. Nat. Genet. 2005, 37, 1217–1223. [Google Scholar] [CrossRef] [PubMed]
- Frazer, K.A.; Ballinger, D.G.; Cox, D.R.; Hinds, D.A.; Stuve, L.L.; Gibbs, R.A.; Belmont, J.W.; Boudreau, A.; Hardenbol, P.; Leal, S.M.; et al. A second generation human haplotype map of over 3.1 million SNPs. Nature 2007, 449, 851–861. [Google Scholar] [CrossRef] [PubMed]
- Huang, S.P.; Huang, L.C.; Ting, W.C.; Chen, L.M.; Chang, T.Y.; Lu, T.L.; Lan, Y.H.; Liu, C.C.; Yang, W.H.; Lee, H.Z.; et al. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy. Cancer Epidemiol. Biomark. Prev. 2009, 18, 3068–3074. [Google Scholar] [CrossRef] [PubMed]
- Storey, J.D.; Tibshirani, R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. USA 2003, 100, 9440–9445. [Google Scholar] [CrossRef] [PubMed]
- Ward, L.D.; Kellis, M. Haploreg: A resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res. 2012, 40, D930–D934. [Google Scholar] [CrossRef] [PubMed]
- Lonsdale, J.; Thomas, J.; Salvatore, M.; Phillips, R.; Lo, E.; Shad, S.; Hasz, R.; Walters, G.; Garcia, F.; Young, N.; et al. The genotype-tissue expression (GTEx) project. Nat. Genet. 2013, 45, 580–585. [Google Scholar] [CrossRef] [PubMed] [Green Version]
SNP | Location | Allele | Event a | No Event a | Best Model | HR (95% CI) b | p b | q |
---|---|---|---|---|---|---|---|---|
rs3846716 | 5′ upstream | G>A | 295/117/12 | 22/11/2 | Dominant | 0.67 (0.53–0.84) | <0.001 | 0.009 |
rs2289485 | Intron | T>G | 371/54/2 | 30/5/1 | Additive | 0.74 (0.56–0.99) | 0.040 | 0.093 |
rs2707765 | Intron | G>C | 210/176/38 | 16/15/4 | Additive | 0.78 (0.67–0.91) | 0.002 | 0.009 |
rs2431238 | Intron | C>T | 343/76/2 | 30/4/1 | Additive | 0.77 (0.60–0.99) | 0.044 | 0.093 |
rs41115 | Thr1493Thr | T>C | 300/114/14 | 25/9/2 | Dominant | 0.71 (0.57–0.89) | 0.003 | 0.012 |
rs497844 | 3′ downstream | C>T | 301/107/15 | 24/10/1 | Dominant | 0.68 (0.54–0.85) | 0.001 | 0.009 |
SNP | Location | Allele | Event a | No Event a | Best Model | HR (95% CI) b | p b | q |
---|---|---|---|---|---|---|---|---|
rs3846716 | 5′ upstream | G>A | 106/32/2 | 211/96/12 | Additive | 0.65 (0.44–0.95) | 0.026 | 0.055 |
rs2289485 | Intron | T>G | 129/12/0 | 272/47/3 | Additive | 0.46 (0.25–0.86) | 0.014 | 0.054 |
rs2707765 | Intron | G>C | 77/54/9 | 149/137/33 | Additive | 0.68 (0.51–0.91) | 0.009 | 0.043 |
rs17134945 | Intron | A>G | 130/12/0 | 276/43/3 | Additive | 0.52 (0.28–0.95) | 0.033 | 0.057 |
rs41115 | Thr1493Thr | T>C | 108/31/3 | 217/92/13 | Dominant | 0.62 (0.41–0.95) | 0.026 | 0.055 |
rs497844 | 3′ downstream | C>T | 110/27/3 | 215/90/13 | Dominant | 0.51 (0.33–0.80) | 0.003 | 0.043 |
No. of Protective Alleles a | Overall Patients, n | Disease Progression | ACM | ||||||
---|---|---|---|---|---|---|---|---|---|
Events, n | Median, mo | HR (95% CI) b | p b | Events, n | Median, mo | HR (95% CI) b | p b | ||
0 | 225 | 109 | 17 | 1.00 | - | 77 | 108 | 1.00 | - |
1 | 93 | 86 | 20 | 0.91 (0.70–1.18) | 0.467 | 30 | 142 | 0.76 (0.48–1.20) | 0.240 |
2 | 105 | 96 | 23 | 0.72 (0.55–0.93) | 0.012 | 27 | 145 | 0.60 (0.37–0.97) | 0.037 |
3–4 | 35 | 32 | 29 | 0.56 (0.38–0.83) | 0.004 | 6 | NR c | 0.36 (0.16–0.84) | 0.018 |
Trend | - | - | - | 0.84 (0.76–0.93) | <0.001 | - | - | 0.75 (0.62–0.90) | 0.003 |
© 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Geng, J.-H.; Lin, V.C.; Yu, C.-C.; Huang, C.-Y.; Yin, H.-L.; Chang, T.-Y.; Lu, T.-L.; Huang, S.-P.; Bao, B.-Y. Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy. Int. J. Mol. Sci. 2016, 17, 1970. https://doi.org/10.3390/ijms17121970
Geng J-H, Lin VC, Yu C-C, Huang C-Y, Yin H-L, Chang T-Y, Lu T-L, Huang S-P, Bao B-Y. Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy. International Journal of Molecular Sciences. 2016; 17(12):1970. https://doi.org/10.3390/ijms17121970
Chicago/Turabian StyleGeng, Jiun-Hung, Victor C. Lin, Chia-Cheng Yu, Chao-Yuan Huang, Hsin-Ling Yin, Ta-Yuan Chang, Te-Ling Lu, Shu-Pin Huang, and Bo-Ying Bao. 2016. "Inherited Variants in Wnt Pathway Genes Influence Outcomes of Prostate Cancer Patients Receiving Androgen Deprivation Therapy" International Journal of Molecular Sciences 17, no. 12: 1970. https://doi.org/10.3390/ijms17121970